CRISPR Therapeutics AG (CRSP) shares declined 7.82 percent to $54.19, down $4.59 on Tuesday, after the company announced plans to offer $350 million in convertible senior notes.
The stock is currently trading at $54.19 compared with its previous close of $58.78. Shares opened at $53.92 and traded between $53.11 and $55.40 during the session on the Nasdaq. Trading volume reached about 1.90 million shares, slightly above the average volume of about 1.65 million shares.
CRISPR Therapeutics said the convertible senior notes due 2031 will be offered in a private placement, with initial purchasers having a 13-day option to buy up to an additional $52.5 million of the notes. The company said it plans to use the net proceeds for general corporate purposes. The stock has traded between $30.04 and $78.48 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.